Comparison
Company
Score
Quality
Valuation
Financial
Technical
Why is CARsgen Therapeutics Holdings Ltd. ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
- Poor long term growth as Net Sales has grown by an annual rate of 209.39% and Operating profit at 3.37% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -73.62
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 47.75%, its profits have risen by 52.1%
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is CARsgen Therapeutics Holdings Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
CARsgen Therapeutics Holdings Ltd.
47.75%
1.87
81.22%
Hang Seng Hong Kong
18.06%
0.71
25.51%
Quality key factors
Factor
Value
Sales Growth (5y)
209.39%
EBIT Growth (5y)
3.37%
EBIT to Interest (avg)
-73.62
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.30
Sales to Capital Employed (avg)
0.03
Tax Ratio
0.10%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
12.55
EV to EBIT
-26.01
EV to EBITDA
-29.56
EV to Capital Employed
-37.98
EV to Sales
130.86
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-34.19%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Movement
12What is working for the Company
NET SALES(HY)
Higher at HKD 54.74 MM
RAW MATERIAL COST(Y)
Fallen by -3,615% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 2%
OPERATING PROFIT(Q)
Highest at HKD -137.63 MM
PRE-TAX PROFIT(Q)
Highest at HKD -81.08 MM
NET PROFIT(Q)
Highest at HKD -81.08 MM
EPS(Q)
Highest at HKD -0.15
-1What is not working for the Company
CASH AND EQV(HY)
Lowest at HKD 1,381.23 MM
Here's what is working for CARsgen Therapeutics Holdings Ltd.
Net Sales
Higher at HKD 54.74 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (HKD MM)
Operating Profit
Highest at HKD -137.63 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (HKD MM)
Pre-Tax Profit
Highest at HKD -81.08 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (HKD MM)
Pre-Tax Profit
At HKD -81.08 MM has Grown at 78.72%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (HKD MM)
Net Profit
Highest at HKD -81.08 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (HKD MM)
Net Profit
At HKD -81.08 MM has Grown at 78.72%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (HKD MM)
EPS
Highest at HKD -0.15
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (HKD)
Debtors Turnover Ratio
Highest at 2%
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -3,615% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for CARsgen Therapeutics Holdings Ltd.
Cash and Eqv
Lowest at HKD 1,381.23 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents






